Uzbekistan cough syrup deaths | Process underway to cancel license of Marion Biotech, says official

On Friday, the local police arrested three senior employees of the firm after an FIR was lodged against them on charges of manufacturing and sale of adulterated drugs.

March 05, 2023 06:47 pm | Updated 08:07 pm IST - Noida

Logo of Marion Biotech, a healthcare and pharmaceutical company is seen on a gate outside their office in Noida. | File photo

Logo of Marion Biotech, a healthcare and pharmaceutical company is seen on a gate outside their office in Noida. | File photo | Photo Credit: Reuters

The process has been initiated for cancellation of the drug license of pharmaceutical firm Marion Biotech, which is allegedly linked with the death of 18 children in Uzbekistan who consumed their cough syrup in December 2022, officials here said on Sunday.

All production of drugs and other activities at the firm's campus in Sector 67 here have also been stopped completely, Gautam Buddh Nagar drug inspector Vaibhav Babbar said.

On Friday, the local police arrested three senior employees of the firm after an FIR was lodged against them on charges of manufacturing and sale of adulterated drugs.

The two directors of the company named in the FIR, however, still remain at large.

“The process has been initiated for cancellation of the drug license of pharmaceutical firm Marion Biotech. Paperwork for it is in progress and a report has been sent to the Uttar Pradesh government," Mr. Babbar told PTI.

"All production at the firm had been suspended in January itself and now it has been completely stopped,” he said.

Marion Biotech had come under the scanner in December over reports of the children's death in Uzbekistan after which India's Central Drugs Standard Control Organisation (CDSCO) initiated a probe into the matter and found 22 out of 36 samples “not of standard quality” (adulterated and spurious).

The World Health Organization had also declared a “medical product alert” related to Marion Biotech's drugs in the wake of the deaths reported in Uzbekistan.

The cough syrup 'Dok-1 Max', which was under the spotlight, has no domestic market in India and it was only an export item, the drug inspector said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.